Stocktoria
Iterum Therapeutics plc ITRMF
OTC · stock · Pharmaceutical Preparations · website · IPO 2018-05-25
Iterum Therapeutics plc financials (annual, from 10-K)
Bars are annual figures from 2017 to 2024; red bars are negative (a loss or cash outflow).
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0 | $0 | $37,000 | $869,000 | $508,000 |
| R&D expense | $10.5M | $40.0M | $17.6M | $10.7M | $21.1M | $90.8M | $68.6M | $25.5M |
| Operating income | -$18.7M | -$47.5M | -$30.4M | -$24.5M | -$32.1M | -$102.0M | -$76.6M | -$29.5M |
| Income tax | $240,000 | $613,000 | $301,000 | $705,000 | $743,000 | $444,000 | $472,000 | $444,000 |
| Net income | -$24.8M | -$38.4M | -$44.4M | -$91.6M | -$52.0M | -$103.1M | -$77.1M | -$29.4M |
| EPS (diluted) | $-1.26 | $-2.96 | $-3.63 | $-8.41 | $-32.49 | — | — | — |
| Operating cash flow | -$26.8M | -$39.3M | -$18.5M | -$15.8M | -$54.5M | -$81.9M | -$77.3M | -$30.6M |
| Free cash flow | -$26.8M | -$39.3M | -$18.5M | -$15.9M | -$54.5M | -$81.9M | -$77.3M | -$31.4M |
| Cash & equivalents | $24.1M | $6.1M | $21.1M | $27.4M | $14.5M | $4.8M | $44.6M | $8.5M |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total assets | $44.6M | $26.3M | $66.8M | $91.5M | $32.8M | $25.8M | $97.9M | $46.8M |
| Total liabilities | $48.7M | $32.7M | $38.8M | $41.3M | $83.4M | $52.0M | $26.2M | $7.2M |
| Shareholders' equity | -$4.1M | -$6.4M | $28.0M | $50.2M | -$50.6M | -$26.2M | $71.6M | $39.5M |
Growth · year-over-year
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue growth | — | — | — | — | -100.0% | -95.7% | +71.1% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Source: SEC EDGAR filings · CIK 0001659323 · US · as of 2024-12-31. facts plus Stocktoria's own computed scores — not investment advice.